Ownership Capital B.V. Sells 27,764 Shares of Illumina, Inc. (NASDAQ:ILMN)

Ownership Capital B.V. lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 813,734 shares of the life sciences company’s stock after selling 27,764 shares during the period. Illumina comprises about 2.5% of Ownership Capital B.V.’s investment portfolio, making the stock its 18th biggest position. Ownership Capital B.V.’s holdings in Illumina were worth $113,304,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Eukles Asset Management grew its holdings in Illumina by 1.7% in the 3rd quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company’s stock worth $816,000 after acquiring an additional 100 shares during the last quarter. Clear Creek Financial Management LLC boosted its stake in shares of Illumina by 6.3% during the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after purchasing an additional 100 shares in the last quarter. Lido Advisors LLC boosted its stake in shares of Illumina by 6.1% during the 3rd quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company’s stock valued at $255,000 after purchasing an additional 107 shares in the last quarter. Quent Capital LLC boosted its stake in shares of Illumina by 45.2% during the 4th quarter. Quent Capital LLC now owns 363 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 113 shares in the last quarter. Finally, Independent Advisor Alliance boosted its stake in shares of Illumina by 8.6% during the 3rd quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company’s stock valued at $219,000 after purchasing an additional 126 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN traded up $1.23 during mid-day trading on Friday, hitting $122.28. 829,331 shares of the company traded hands, compared to its average volume of 1,470,247. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a 50-day moving average price of $131.51 and a two-hundred day moving average price of $127.39. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $213.91. The stock has a market cap of $19.47 billion, a price-to-earnings ratio of -16.66 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the previous year, the company earned $0.14 earnings per share. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. Equities analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

ILMN has been the topic of a number of research reports. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Barclays lifted their target price on shares of Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. TD Cowen cut shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a research report on Thursday, January 4th. Finally, OTR Global reissued a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $167.70.

Insider Activity

In related news, CEO Jacob Thaysen acquired 7,330 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.17% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.